Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.82 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.82 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | PKM | P14618 | 3/20 | 0.57 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6127516 | 1.00 | CYP2D6 (0.82) | CYP2D6CYP2C9CYP2C19TSHRALDH1A1 | |
| SCHEMBL27601052 | 0.92 | CYP2D6 (0.70) | CYP2D6CYP2C9CYP2C19TSHRALDH1A1 | |
| SCHEMBL23052533 | 0.90 | CYP2D6 (0.72) | CYP2D6CYP2C9CYP2C19TSHRALDH1A1 | |
| SCHEMBL20211031 | 0.90 | CYP2D6 (0.72) | CYP2D6CYP2C9CYP2C19TSHRALDH1A1 | |
| SCHEMBL1164461 | 0.88 | CYP2D6 (0.74) | CYP2D6CYP2C9CYP2C19TSHRALDH1A1 | |
| SCHEMBL10690110 | 0.88 | TSHR (0.89) | CYP2D6CYP2C9CYP2C19TSHRALDH1A1 | |
| SCHEMBL6122455 | 0.88 | TSHR (0.70) | CYP2D6CYP2C9CYP2C19TSHRALDH1A1 | |
| SCHEMBL27583579 | 0.86 | CYP2D6 (0.61) | CYP2D6CYP2C9CYP2C19TSHRALDH1A1 | |
| SCHEMBL27583581 | 0.86 | CYP2D6 (0.61) | CYP2D6CYP2C9CYP2C19TSHRALDH1A1 | |
| SCHEMBL29208934 | 0.84 | CYP2D6 (0.68) | CYP2D6CYP2C9CYP2C19TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190210992-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE (US) | 2019-07-11 | — | — | US | disclosed |
| US-10287264-B2 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | TEXAS HEART INSTITUTE (US) | 2019-05-14 | — | — | US | disclosed |
| EP-3388429-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | Texas Heart Institute (US) | 2018-10-17 | — | — | EP | disclosed |
| US-10071980-B2 | Agonists that enhanced binding of integrin-expressing cells to integrin receptors | TEXAS HEART INSTITUTE (US) | 2018-09-11 | — | — | US | disclosed |
| US-10035784-B2 | Agonists that enhanced binding of integrin-expressing cells to integrin receptors | TEXAS HEART INSTITUTE (US) | 2018-07-31 | — | — | US | disclosed |
| EP-2881392-B1 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | TEXAS HEART INST (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-2881393-B1 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | TEXAS HEART INST (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-2640721-B1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INST (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-3164127-A1 | COMPOSITIONS AND METHODS TO IMPROVE ADOPTIVE CELL THERAPIES | 7 HILLS INTERESTS, LLC (US) | 2017-05-10 | — | — | EP | disclosed |
| US-20170044130-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE | 2017-02-16 | — | — | US | disclosed |
| US-9512109-B2 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | TEXAS HEART INSTITUTE (US) | 2016-12-06 | — | — | US | disclosed |
| WO-2016003980-A1 | COMPOSITIONS AND METHODS TO IMPROVE ADOPTIVE CELL THERAPIES | 7 HILLS INTERESTS LLC (US) | 2016-01-07 | — | — | WO | disclosed |
| US-20150368234-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE | 2015-12-24 | — | — | US | disclosed |
| US-20150291571-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE | 2015-10-15 | — | — | US | disclosed |
| EP-2881392-A1 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | Texas Heart Institute (US) | 2015-06-10 | — | — | EP | disclosed |
| EP-2881393-A1 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | Texas Heart Institute (US) | 2015-06-10 | — | — | EP | disclosed |
| EP-2640721-A2 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | Texas Heart Institute (US) | 2013-09-25 | — | — | EP | disclosed |
| US-20130236434-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE (US) | 2013-09-12 | — | — | US | disclosed |
| WO-2012068251-A2 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE (US) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035784-B2 | Agonists that enhanced binding of integrin-expressing cells to integrin receptors | ITGB7, ITGAL, ITGB1 | CYP2D6 4193/4885CYP2C9 3643/4885CYP2C19 3673/4885 |
| US-20190210992-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | CYP2D6 3999/4885CYP2C9 3677/4885CYP2C19 3602/4885 |
| US-20130236434-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | CYP2D6 4187/4885CYP2C9 3744/4885CYP2C19 3742/4885 |
| US-10287264-B2 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | ITGB7, ITGAL, ITGB1 | CYP2D6 4187/4885CYP2C9 3744/4885CYP2C19 3742/4885 |
| US-20170044130-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | CYP2D6 4187/4885CYP2C9 3744/4885CYP2C19 3742/4885 |
| US-20150291571-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | CYP2D6 4193/4885CYP2C9 3643/4885CYP2C19 3673/4885 |
| US-20150368234-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | CYP2D6 4193/4885CYP2C9 3643/4885CYP2C19 3673/4885 |
| US-10071980-B2 | Agonists that enhanced binding of integrin-expressing cells to integrin receptors | ITGB7, ITGAL, ITGB1 | CYP2D6 4193/4885CYP2C9 3643/4885CYP2C19 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.